Corporate Reputation of Pharma Companies, 2017-2018 - Patient Perspective of Respiratory Patients - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective - Respiratory Edition" report has been added to ResearchAndMarkets.com's offering.

State of relationships between respiratory patient groups and the pharmaceutical industry

42% of the respiratory patient groups respondent to the 2017 'Corporate Reputation of Pharma' survey stated that pharma industry's overall corporate reputation was Excellent or Good that year. Though down on the equivalent 2016 figure of 51%, the 2017 figure from respiratory patient groups was on a par with that reported by the full respondent body of 1,330 patient groups therapy wide.

Respiratory patient groups felt (more so than patient groups from most other therapy areas) that the pharmaceutical industry performed all its key activities well in 2017. The three graphs below show generally positive attitudes from respiratory patient groups to three examples of these pharma activities: patient centricity; patient information; and transparency in the funding of external healthcare stakeholders.

Key Topics Covered:

1. Executive Summary
2. The Relationships That Respiratory Patient Groups Have With Pharma, 2017
3. Industry-Wide Findings From Respiratory Patient Groups, 2017
4. Rankings Of The 11 Pharma Companies, 2017 V. 2016 Among Respiratory Patient Groups Familiar With The Companies
5. Positioning Of Nine Pharma Companies, 2017 V. 2016 Among Respiratory Patient Groups That Work/Partner With The Companies
6. Profiles Of The 11 Companies, 2017

Companies Mentioned

• AstraZeneca
• Bayer
• Boehringer-Ingelheim
• Chiesi Farmaceutici
• GSK
• Merck & Co/MSD
• Novartis
• Pfizer
• Roche (Genentech in the US)
• Sanofi
• Teva

For more information about this report visit https://www.researchandmarkets.com/research/kkmwv3/corporate?w=4